Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03740529 · ClinicalTrials.gov registry record · Phase 1
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
A Phase 1 study, sponsored by Loxo Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 803
- Enrollment target
NCT03740529: Completed Phase 1 study, sponsored by Loxo Oncology.
NCT03740529 is a Phase 1 study that has completed, run by Loxo Oncology. The registered enrollment target is 803 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1238% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03740529, a Phase 1 study, has completed, sponsored by Loxo Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 803 participants
- Enrollment target
Study Summary
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Primary Outcome
Phase I
Interventions
- DRUG Venetoclax
- DRUG Rituximab
- DRUG Pirtobrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 1 |
What the finished NCT03740529 record still lists
NCT03740529 is an interventional study that assigns participants to a tested intervention. The registered 803 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (1238% higher).
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT03740529 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03740529 about?
NCT03740529 is a clinical study titled "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL". This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
What is the current status of trial NCT03740529?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 803 participants. The study started on 2019-03-15. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT03740529?
The interventions under investigation include: Venetoclax (DRUG), Rituximab (DRUG), Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT03740529?
This trial is sponsored by Loxo Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03740529's enrollment target sits among peer trials
803 12th of 2000 higher than 1,989 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI